Literature DB >> 2867915

The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist.

E H Ohlstein, B Zabko-Potapovich, B A Berkowitz.   

Abstract

The alpha-adrenoceptor activity of fenoldopam was evaluated in three different in vitro tissue preparations. In rabbit isolated aortic rings fenoldopam displayed weak alpha 1-adrenoceptor antagonist activity (-log KB = 5.41) and displayed no alpha 1-adrenoceptor agonist activity. In contrast, fenoldopam demonstrated moderately potent antagonist properties at the alpha 2-adrenoceptor in two other tissue preparations. In in vitro model systems used for the characterization of alpha 2-adrenoceptors, fenoldopam competitively antagonized the effects of the alpha 2-adrenoceptor agonist B-HT 920. In the dog isolated saphenous vein and in the isolated field-stimulated guinea-pig ileum, fenoldopam antagonized the effects of B-HT 920 with -log KB values of 7.78 and 7.60, respectively. These data indicate that in addition to being an agonist at DA1 receptors, fenoldopam is also a relatively selective antagonist at alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867915     DOI: 10.1016/0014-2999(85)90143-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist.

Authors:  S S Ng; C C Pang
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 2.  New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Authors:  P T Horn; M B Murphy
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.

Authors:  W D Kerns; E Arena; D G Morgan
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

5.  Influence of the dopamine receptor agonists fenoldopam and quinpirole in the rat superior mesenteric vascular bed.

Authors:  A G Dupont; R A Lefebvre; P Vanderniepen
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

Review 6.  Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

7.  Analysis of the agonist activity of fenoldopam (SKF 82526) at the vascular 5-HT2 receptor.

Authors:  M I Christie; D Harper; G W Smith
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

8.  FPL 63012AR: a potent D1-receptor agonist.

Authors:  G W Smith; J B Farmer; F Ince; K Matu; P D Mitchell; I Naya; B Springthorpe
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

Review 9.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

10.  The effects of quinpirole and fenoldopam on the potassium-evoked overflow of endogenous dopamine and noradrenaline in dog mesenteric arteries.

Authors:  P Soares-da-Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.